» Articles » PMID: 37369946

Cancer Metastasis Under the Magnifying Glass of Epigenetics and Epitranscriptomics

Overview
Specialty Oncology
Date 2023 Jun 27
PMID 37369946
Authors
Affiliations
Soon will be listed here.
Abstract

Most of the cancer-associated mortality and morbidity can be attributed to metastasis. The role of epigenetic and epitranscriptomic alterations in cancer origin and progression has been extensively demonstrated during the last years. Both regulations share similar mechanisms driven by DNA or RNA modifiers, namely writers, readers, and erasers; enzymes responsible of respectively introducing, recognizing, or removing the epigenetic or epitranscriptomic modifications. Epigenetic regulation is achieved by DNA methylation, histone modifications, non-coding RNAs, chromatin accessibility, and enhancer reprogramming. In parallel, regulation at RNA level, named epitranscriptomic, is driven by a wide diversity of chemical modifications in mostly all RNA molecules. These two-layer regulatory mechanisms are finely controlled in normal tissue, and dysregulations are associated with every hallmark of human cancer. In this review, we provide an overview of the current state of knowledge regarding epigenetic and epitranscriptomic alterations governing tumor metastasis, and compare pathways regulated at DNA or RNA levels to shed light on a possible epi-crosstalk in cancer metastasis. A deeper understanding on these mechanisms could have important clinical implications for the prevention of advanced malignancies and the management of the disseminated diseases. Additionally, as these epi-alterations can potentially be reversed by small molecules or inhibitors against epi-modifiers, novel therapeutic alternatives could be envisioned.

Citing Articles

Beyond destruction: emerging roles of the E3 ubiquitin ligase Hakai.

Escuder-Rodriguez J, Rodriguez-Alonso A, Jove L, Quiroga M, Alfonsin G, Figueroa A Cell Mol Biol Lett. 2025; 30(1):9.

PMID: 39833727 PMC: 11749156. DOI: 10.1186/s11658-025-00693-y.


The role of genetic diversity, epigenetic regulation, and sex-based differences in HIV cure research: a comprehensive review.

Letchumanan P, Das K Epigenetics Chromatin. 2025; 18(1):1.

PMID: 39754177 PMC: 11697457. DOI: 10.1186/s13072-024-00564-4.


Epigenetic frontiers: miRNAs, long non-coding RNAs and nanomaterials are pioneering to cancer therapy.

Prabhakaran R, Thamarai R, Sivasamy S, Dhandayuthapani S, Batra J, Kamaraj C Epigenetics Chromatin. 2024; 17(1):31.

PMID: 39415281 PMC: 11484394. DOI: 10.1186/s13072-024-00554-6.


New players in the landscape of renal cell carcinoma bone metastasis and therapeutic opportunities.

Cesana B, Cochet C, Filhol O Int J Cancer. 2024; 156(3):475-487.

PMID: 39306698 PMC: 11622000. DOI: 10.1002/ijc.35181.


Epigenetic Modifiers in Cancer Metastasis.

Hu D, Zhao T, Xu C, Pan X, Zhou Z, Wang S Biomolecules. 2024; 14(8).

PMID: 39199304 PMC: 11352731. DOI: 10.3390/biom14080916.


References
1.
Hyun K, Jeon J, Park K, Kim J . Writing, erasing and reading histone lysine methylations. Exp Mol Med. 2017; 49(4):e324. PMC: 6130214. DOI: 10.1038/emm.2017.11. View

2.
Zhu S, Wu Y, Zhang X, Peng S, Xiao H, Chen S . Targeting N-methylguanosine tRNA modification blocks hepatocellular carcinoma metastasis after insufficient radiofrequency ablation. Mol Ther. 2022; 31(6):1596-1614. PMC: 10278047. DOI: 10.1016/j.ymthe.2022.08.004. View

3.
Song G, Zhang Y, Wang L . MicroRNA-206 targets notch3, activates apoptosis, and inhibits tumor cell migration and focus formation. J Biol Chem. 2009; 284(46):31921-7. PMC: 2797263. DOI: 10.1074/jbc.M109.046862. View

4.
Riihimaki M, Thomsen H, Hemminki A, Sundquist K, Hemminki K . Comparison of survival of patients with metastases from known versus unknown primaries: survival in metastatic cancer. BMC Cancer. 2013; 13:36. PMC: 3565900. DOI: 10.1186/1471-2407-13-36. View

5.
Chen X, Li A, Sun B, Yang Y, Han Y, Yuan X . 5-methylcytosine promotes pathogenesis of bladder cancer through stabilizing mRNAs. Nat Cell Biol. 2019; 21(8):978-990. DOI: 10.1038/s41556-019-0361-y. View